Clinical Trial Detail

NCT ID NCT03448042
Title A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications

breast cancer

Advanced Solid Tumor

stomach cancer

gastroesophageal junction adenocarcinoma

Therapies

BTRC 4017A

Age Groups: adult senior

Additional content available in CKB BOOST